Immunovant : Corporate Overview

Corporate Overview

January 2021

Forward-looking statements

This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "expect," "plan," "anticipate," "believe," "estimate," "intend," "future," "potential," "continue" and other similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. For example, forward-looking statements include statements Immunovant makes regarding its business strategy, its plans to develop and commercialize its product candidates, the potential safety and efficacy of Immunovant's current or future product candidates, its expectations regarding timing, the design and results of clinical trials of its product candidates, Immunovant's plans and expected timing with respect to regulatory filings and approvals, the size and growth potential of the markets for Immunovant's product candidates, and its ability to serve those markets. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this presentation; any product candidates that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of the ongoing COVID-19 pandemic on Immunovant's clinical development plans and timelines; Immunovant's business is heavily dependent on the successful development, regulatory approval and commercialization of its sole product candidate, IMVT-1401; Immunovant is at an early stage in development of IMVT-1401; and Immunovant will require additional capital to fund its operations and advance IMVT-1401 through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled "Risk Factors" in Immunovant's most recent Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Our vision: Normal lives for patients with autoimmune diseases

Our asset: IMVT-1401, a novel, fully human monoclonal antibody inhibiting FcRn-mediated recycling of IgG

Our strategy for IMVT-1401:

• Be best-in-classin target indications where anti-FcRn mechanism has already established clinical proof-of-concept
• Be firstto study FcRn inhibition in target indications with clear biologic rationale and no known in-class competition

Our near-termvalue drivers: Two data readouts expected before Q3 2021

Our intellectual property: Patent estate provides composition-of-matter and method-of-use protection until at least 2035in the U.S. (other jurisdictions pending)

Our balance sheet: Approximately $444 million in cash as of September 30, 2020

3

IMVT-1401: A pipeline in a product

T a r g e t I n d i c a t i o n		2H20		1H21		2H21	A n t i c i p a t e d
			M i l e s t o n e s
Myasthenia Gravis (MG)					MG Phase 3		Phase 3 initiation
					expected in 1H21
Thyroid Eye Disease									Phase 2b results
	ASCEND GO-2
(TED)							expected in 3Q21
Warm Autoimmune									Phase 2a Cohort 1 results
	ASCEND WAIHA
Hemolytic Anemia
							expected in 2Q21
(WAIHA)
Indication #4		Indication #4						Three new indications
									expected to be
									announced by Aug '21
Indication #5		Indication #5

Indication #6

Indication #6

4